Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
140.5 EUR | -1.23% | -8.97% | -10.82% |
Apr. 26 | Transcript : IMCD N.V., Q1 2024 Earnings Call, Apr 26, 2024 | |
Apr. 24 | IMCD's Spanish Unit to Buy Cobapharma | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.79 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.82% | 8.65B | A- | ||
+34.89% | 1.07B | - | ||
+10.50% | 177M | - | - | |
+54.79% | 161M | - | - | |
+7.32% | 115M | - | - | |
+3.54% | 114M | - | - | |
+7.62% | 87.17M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IMCD Stock
- Ratings IMCD N.V.